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Nanoparticles are key components underlying recent technological advances in various industrial and
medical ﬁelds, and thus understanding their mode of interaction with biological systems is essential.
However, while several nanoparticle systems have been shown to interact with blood platelets, many
questions remain concerning the mechanisms of platelet activation and the role that the
physicochemical properties of nanoparticles play in inducing platelet aggregation. Here, using negatively
charged polystyrene nanoparticles with sizes of 25, 50, 119, 151, 201 nm and negatively charged platinum
nanoparticles with sizes of 7 and 73 nm, we show that it is not the size of the nanoparticles but rather
the nanoparticle surface area that is critical in mediating the eﬀects on platelet activation. The
nanoparticles stimulate platelet aggregation through passive (agglutination) and activation of integrin
aIIbb3 through a pathway regulated by Src and Syk tyrosine kinase.Introduction
Nanoparticles can be tailored with a diverse range of distinctive
physicochemical properties, inducing a plethora of eﬀects upon
interaction with biological systems.1,2 They can have benecial,
therapeutic or adverse biological eﬀects depending on their
characteristics. In this context, the interaction of nanoparticles
with platelets may contribute to an undesirable inuence on
haemostasis or lead to thrombosis. Platelets are central to
a healthy vascular system where they maintain haemostasis at
sites of injury or inammation. However, excessive activation of
platelets, which leads to their aggregation, is a causative factor
for thrombotic diseases that can result in such events as
a stroke or heart attack.3
Several studies have demonstrated that engineered nano-
particles can interact with platelets in diﬀerent ways causing
either no eﬀect,4 inhibition,5 and passive (agglutination) or
active (integrin aIIbb3-dependent) aggregation.6,7 While the
mechanisms and critical factors that drive these eﬀects on
platelet function are not yet fully elucidated,8 there is increasing
evidence that nanoparticle material, shape, size, surface
chemistry, surface charge and concentration inuence theof Engineering and Physical Sciences,
ail: p.m.mendes@bham.ac.uk
(COMPARE), Universities of Birmingham
ity, Birmingham B4 7ET, UK; Web: http://
llege of Medical and Dental Sciences,
ail: S.P.Watson@bham.ac.uk
hemistry 2018platelet response. All have been long understood to inuence
particle mediated health eﬀects.9 For instance, multiwalled and
single-walled carbon nanotubes,7 CdSe quantum dots,10 poly-
styrene nanoparticles11 and dendrimers12 are able to induce
platelet aggregation despite variation in surface charge and
hydrophilicity. On the other hand, in vitro and in vivo studies
have shown that either neutral, positively or negatively charged
nanoparticles can promote changes in platelet activity, with the
degree of activation not only depending on the presence or not
of charge but also the nanoparticle size, shape and composi-
tion.11–15 This intricate relationship between platelet response
and nanoparticle characteristics is a result of diﬀerent mecha-
nisms of platelet activation which depend on the specic
interactions of platelet membrane receptors with nanoparticles.
The nanoparticle–platelet interaction and response may be
mediated either via stimulation of platelet surface receptors10 or
disruption of the platelet membrane.16
One important question concerning the behaviour of nano-
particles is whether diﬀerent nanoparticle sizes can exhibit
diﬀerent functional eﬀects on platelets. A number of studies
suggest that small particles might act diﬀerently from larger
particles.12,15,17,18 For instance, exposure of platelets to den-
drimers of diﬀerent generations (G3, G4, G5 and G6) with sizes
ranging from 3.1 nm to 7.5 nm led to platelet aggregation only
with the larger (G4–G6) dendrimers.12 Another study has sug-
gested that the aggregation eﬀect of 20 nm gold nanoparticles
was stronger than that caused by 70 nm nanoparticles.17 This
trend is, to a certain extent, in accordance with a study on silica
nanoparticles in which platelet aggregation was observed for
10 nm and not 50 nm nanoparticles.18 Since previous size-
dependent eﬀect studies have been based on nanoparticleRSC Adv., 2018, 8, 37789–37794 | 37789
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View Article Onlinemass and moles concentration as the dose metric, it raises the
question on the role that surface area plays in inducing platelet
activation. Are the changes in the biological activity of the
diﬀerent size nanoparticles a result of nanoparticle morphology
or the greater ratio of surface area and number to mass that
occurs as nanoparticle size becomes smaller? Driven by this
fundamental question, so critical to understanding the impact
of nanoparticles in human health, in this study we investigate
the role of nanoparticle surface areamediated eﬀects on platelet
activation. Two diﬀerent nanoparticle materials, namely poly-
styrene (PS) with sizes of 25, 50, 119, 151, 201 nm and platinum
(Pt) with sizes of 7 and 73 nm were used to study active platelet
aggregation in a surface area-dependent manner.
Experimental
Chemical and materials
Commercially available chemicals were purchased from Aldrich
Chemicals and Fisher Chemicals and used as received. Poly-
styrene nanoparticles were purchased from Polysciences Inc
(50 nm; 119 nm; 201 nm) and Bangs Laboratories (25 nm and
151 nm). Dasatinib was from LC-Laboratories; PRT-060318 from
Portola Pharmaceuticals and eptibatide (Integrilin) from
GlaxoSmithKline.
Preparation of Pt nanoparticles
Pt nanoparticles were prepared by adapting the multistep seed-
mediated growth protocol reported by Bigall and co-workers.19
To begin with, the small (seed) nanoparticles were prepared. A
3.6 ml of a 0.2% (w/v) solution of chloroplatinic acid hexahy-
drate was added to 46.4 ml of boiling double distilled water.
Aer 1 min of stirring, a 1.1 ml solution of 1% (v/v) sodium
citrate and 0.05% (v/v) citric acid solution was added. Half
a minute later, a freshly prepared solution (0.55 ml) containing
0.08% (v/v) of sodium borohydride, 1% (v/v) sodium citrate and
0.05% (v/v) citric acid was quickly injected. Following stirring
for 10 min, the solution was cooled down to room temperature.
These small nanoparticles act as the templates for the
growth of the larger nanoparticles in further reaction steps. To
50 ml of water, 100 ml of nanoparticle seeds prepared as
described above and 450 ml of chloroplatinic acid hexahydrate
(0.4 M) were added and mixed at room temperature. To this
solution, 5 ml of reducing agent (1.25% (v/v) ascorbic acid and
1% (v/v) sodium citrate) was added dropwise, aer which the
mixture was heated to boiling and le to react under stirring for
45 min. The product thus obtained was puried by centrifuga-
tion (30 min, 444g) using acetone as the precipitation solvent.
Following this, the product was re-dispersed using a mixture of
1 : 4 v/v solution of acetone : water before centrifuging again.
This process was repeated 2 times.
Transmission electron microscopy
A drop of the nanoparticle solution (10 ml) was deposited onto
a carbon coated TEM specimen grid (300 mesh, Agar Scientic)
and Bright-eld imaging was performed using a JEOL 1200ex
LaB6 TEM at an accelerating voltage of 80 kV. Particle size37790 | RSC Adv., 2018, 8, 37789–37794distributions were calculated from TEM images using the so-
ware ImageJ. The diameters of 200 individual particles were
measured to attain the average nanoparticle size fromwhich the
standard deviation and frequency size distribution graphs were
generated.
Zeta potential
The zeta potential was measured using a Zetasizer instrument
(Malvern Nanosizer Nano ZS) equipped with a red laser light
source (HeNe laser operating at l ¼ 632.8 nm) used at 173
backscatter detection mode. The nanoparticles were suspended
in the synthesis solvent (double distilled water) or Tyrode's-
HEPES buﬀer (pH 7.3; 134 mM NaCl, 2.90 mM KCl, 0.34 mM
Na2HPO4 : 12H2O, 12 mM NaHCO3, 20 mM HEPES, 1 mM
MgCl2 and 10 mM glucose) and were sonicated prior to
measurements. Samples were equilibrated at 25 C for 5
minutes before the measurement. Each sample was measured 3
times (10 measurements each) using disposable capillary cells.
Preparation of human platelets
Blood was collected from consenting healthy, drug-free volun-
teers on the day of experiments with 3.8% (w/v) sodium citrate
making up 10% of the nal volume or 3.2% (w/v) sodium citrate
for experiments monitoring aggregation in platelet rich plasma
(PRP). Ethical approval for donation of blood by volunteers was
granted by Birmingham University Internal Ethical Review
(ERN_11-0175). Aer blood collection, acid-citrate-dextrose
(ACD, 10% (v/v)) was added as anti-coagulant. PRP was ob-
tained from anti-coagulated whole blood by centrifuging for
20 min at 200g at room temperature. For the preparation of
washed platelets, the PRP was further centrifuged at 1000g for
10 min at room temperature in the presence of prostacyclin (10
mg ml1) to inhibit platelet activation. The supernatant (plasma)
was discarded and the pellet was resuspended in Tyrode's-
HEPES buﬀer. A further washing step was carried out
following addition of prostacyclin (10 mg ml1) by centrifuging
for 10 min at 1000g. The pellet was re-suspended in Tyrode's-
HEPES buﬀer and the washed platelet concentration was
adjusted to obtain 2 108/ml of washed platelets. Platelets were
le for 30 min at room temperature prior to aggregation
experiments.
Platelet aggregation experiments
Platelets (2  108/ml) were pre-warmed for 3 min before addi-
tion to a Born-aggregometer (ChronoLog). They were then
incubated for 2 min with stirring (1200 rpm) prior to nano-
particle addition. Aggregation was recorded for up to 6 min with
continual stirring. The nal suspension volume was 500 ml.
Each particle size was evaluated at diﬀerent concentrations
(surface area per ml), ranging from 1 cm2 ml1 to 104 cm2 ml1.
The surface area was calculated by considering nanoparticle
surface area and initial nanoparticle concentration in number
of nanoparticles per ml. For the inhibitory studies, the following
inhibitors were given 2 min prior to the agonist: eptibatide (9
mM), dasatinib (10 mM) and PRT-060318 (10 mM). Experiments
were carried out three times and error bars are based onThis journal is © The Royal Society of Chemistry 2018
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View Article Onlinestandard error of the mean. Data was analysed using Graph-
Prism and statistical signicance was determined using a one-
way anova test; diﬀerences were considered signicant at P
value < 0.05.Fig. 1 Nanoparticle induced platelet aggregation in response to
various sizes of polystyrene particles. The % aggregation represents
the diﬀerence in light transmission between the platelet suspension
and a clear solution. The data is from 3 experiments and shown as
mean + SEM.Results and discussion
Five diﬀerent sizes of PS particles displaying similar surface
chemistry were obtained from two diﬀerent suppliers. The
spherical nanoparticles display diameter sizes ranging from 25
to 201 nm with a narrow size distribution as characterised by
TEM and described in Table 1. The PS nanoparticles are
unmodied (i.e. no surface treatment following nanoparticle
preparation) and incorporate sulphate groups on their surfaces
as stated by the manufacturers. In order to understand the
surface charge density and stability of the nanoparticles and
determine how these changes upon exposure to the biological
media used to suspend platelets, the zeta potential of the PS
nanoparticles in water and Tyrode's-HEPES buﬀer was
measured (Table 1). Tyrode's-HEPES buﬀer provides osmotic
buﬀering capacity for platelet cells. Zeta potential measure-
ments revealed that all nanoparticles were negatively charged,
arising from the presence of the sulphate groups on the surface
of the PS nanoparticles. In Tyrode's-HEPES buﬀer, the zeta
potential of the nanoparticles was less negative than in water
due to the compression of the electrical double layer at the high
ionic strength of the Tyrode's-HEPES medium.20 However, all
the nanoparticles exhibit high zeta potential values, ensuring
the stability of the nanoparticle suspension and prevention of
aggregation.
Having established the physicochemical characteristics of
the PS nanoparticles, the eﬀect of size on the functional activity
of human platelets in vitro was investigated. Human washed
platelets were stimulated with PS nanoparticles and monitored
using light transmission aggregometry (LTA). All the nano-
particles induced concentration-dependent platelet aggregation
indicated by the increase in light transmission (Fig. 1). There
was no diﬀerence in the maximal level of aggregation which was
similar to that induced by strong platelet agonists such as
collagen and thrombin.21
The nanoparticles exhibited bell-shaped dose response
curves. Maximum aggregation levels feature at diﬀerent particle
concentrations, with the larger nanoparticles giving rise toTable 1 Average particle size as determined by TEM analysis and zeta
potential of the PS nanoparticles in water (pH ¼ 6.8) and Tyrode's-
HEPES buﬀer (pH ¼ 7.3)
Nanoparticle
Average particle
size + SD (nm)
Zeta potential  SD (mV)
Water
Tyrode's-HEPES
buﬀer
PS-25 25.2  4.9 42.5  2.0 39.4  1.9
PS-50 50.4  4.9 50.8  1.6 35.8  1.6
PS-119 119.2  8.5 35.9  0.7 31.7  1.3
PS-151 150.6  9.7 46.1  1.1 25.2  1.8
PS-201 200.7  10.7 56.3  1.2 33.7  1.4
This journal is © The Royal Society of Chemistry 2018signicant aggregation at lower nanoparticle concentrations.
Importantly, while these results seem supportive of a trend
between nanoparticle size and their potency in causing platelet
aggregation, they do not take into account the nanoparticle
surface area. By considering surface area as a signicant
nanoparticle characteristic, the data shown in Fig. 1 was re-
plotted to illustrate the relationship between surface area and
aggregation (Fig. 2).
As demonstrated in Fig. 2, the re-plotted data produced
similar bell shaped curves, in which all nanoparticle size trends
were super-imposable. These ndings imply that the surface
area of the PS nanoparticles is a critical factor in inducing
platelet activation, independently of nanoparticle size. Thus, if
one considers surface area as the most relevant dose metric,
higher nanoparticle concentrations of the smallest nano-
particles are required to reach similar impact in platelet
aggregation as the largest ones, as supported by the trends
shown in Fig. 1. These results thus highlight not only the
importance of assessing platelet activity in diﬀerent dose
metrics to understand nanoparticle characteristic eﬀects butFig. 2 Nanoparticle induced platelet aggregation in response to
various sizes of PS nanoparticles. The data on the x axis is shown as log
surface area (cm2 ml1). The % aggregation represents the diﬀerence
in light transmission between the platelet suspension and a clear
solution. The data is from 3 experiments and shown as mean + SEM.
RSC Adv., 2018, 8, 37789–37794 | 37791
Fig. 3 TEM images and particle size distributions for the synthesised Pt
nanoparticles with mean diameter + SD of (a) 7.1  1.1 nm and (b) 72.9
 6.0 nm.
Table 2 Zeta potential of the Pt nanoparticles in water (pH ¼ 6.8) and
Tyrode's-HEPES buﬀer (pH ¼ 7.3)
Nanoparticle
Zeta potential  SD (mV)
Water Tyrode's-HEPES buﬀer
Pt-7 59.3  3.2 20.8  0.8
Pt-73 52.3  0.8 22.4  1.3
Fig. 4 (a) Surface area-based dose response curve for platelet
aggregation to platinum nanoparticles (log10 1–4 cm
2 ml1). The
results as shown as the % of the maximal aggregation response. The
data is from 3 experiments and shown as mean + SEM. (b) Repre-
sentative aggregation traces to (i) 7 nm and (ii) 73 nm platinum
RSC Advances Paper
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View Article Onlinealso the predominant role of surface area towards platelet
activation.
In order to elucidate if similar surface area-dependent trend
appears for other nanoparticle types, two diﬀerent sizes Pt
nanoparticles (i.e. 7 nm and 73 nm) were prepared and char-
acterised. Small Pt nanoparticles (7 nm) were synthesized using
a sodium borohydride reduction method and these Pt nano-
particles acted as the seeds for the synthesis of larger Pt nano-
particles (73 nm) using ascorbic acid as the reducing agent.
Sodium citrate and citric acid were used as surfactants to sta-
bilise the nanoparticles, leading to the formation of nano-
particles coated with citrate ions and citric acid. TEM indicates
the formation of monodispersed nanoparticles with spherical
shape and narrow size distribution, with small Pt nanoparticles
having an average diameter of 7.1  1.1 nm and the larger Pt
nanoparticles of 72.9  6.0 nm (Fig. 3).
Zeta potential values for the small and large Pt nanoparticles
when dispersed in both water and Tyrode's-HEPES buﬀer are
reported in Table 2. As expected, the nanoparticles are all
negatively charged due the adsorbed monolayers of citrate and
citric acid on their surfaces. Within the same medium, the
small and large nanoparticles have comparable zeta potential
values. In a similar manner as for the PS nanoparticles, the zeta
potential values obtained for Tyrode's-HEPES buﬀer are lower
than those in water. However, in both media, the nanoparticles
have limited tendency to aggregate since they are highly stable
in water (zeta potential ranges between 52.3 to 59.3 mV) and
moderately stable in Tyrode's-HEPES medium (zeta potential
ranges between 20.8 to 22.4 mV).
Following the characterization of the Pt nanoparticles,
attention was turned to the investigation of the eﬀect of surface
area on the aggregation of human platelets. Fig. 4(a and b(i–ii))
shows the nanoparticles surface area-based dose response curve
for the 7 nm and 73 nm Pt nanoparticles (log10 1–4 cm
2 ml1).
Both particles stimulated rapid aggregation without a notice-
able preceding shape change (which manifests as a decrease in37792 | RSC Adv., 2018, 8, 37789–37794light transmission) and produced a similar bell shaped curve,
with no measureable aggregation at high doses. Platelet aggre-
gation was observed in the middle of the dose range used. The
Pt nanoparticles caused a similar maximal increase in light
transmission to that of the PS nanoparticles and this was not
statistically diﬀerent between the two sized particles (Fig. 5).
In order to place the observations above into a physiological
context of exposure, Pt nanoparticles were tested in platelet rich
plasma (PRP). PRP is highly enriched in clotting factors, growth
factors and proteins such as albumin, brinogen and globulins.
The results in PRP showed that the platinum nanoparticles
(7 nm and 73 nm) did not cause aggregation of platelets (not
shown). Collagen was used as a positive control in which
a typical collagen response was seen, i.e. shape change followednanoparticles.
This journal is © The Royal Society of Chemistry 2018
Fig. 5 Mechanism of aggregation by platinum nanoparticles. Nano-
particle controls were dosed at log10 2.4 cm
2 ml1 as this was the
surface area that induced maximal aggregation. The concentration of
washed platelets was 2  108/ml. Platelets were preincubated with
integrilin (9 mM), dasatinib (10 mM), PRT-060318 (10 mM) or vehicle
(DMSO). Data is the mean + SEM of three experiments. Statistical
analysis is based on a one-way anova and a Tukey test, where (**P <
0.01).
Paper RSC Advances
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
2 
N
ov
em
be
r 2
01
8.
 D
ow
nl
oa
de
d 
on
 1
1/
22
/2
01
8 
3:
21
:2
5 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineby aggregation (not shown). This result is likely to reect non-
specic binding of platinum nanoparticles to plasma
proteins.22–24
To ascertain whether the response to nanoparticle stimula-
tion in washed platelets was mediated by integrin aIIbb3-
dependent aggregation, inhibitory studies were performed
using the aIIbb3 receptor antagonist Integrilin and the Src and
Syk tyrosine kinase inhibitors dasatinib and PRT-060318,
respectively. The rational for these experiments is that the use
of Integrilin will establish whether this is passive (agglutina-
tion) or receptor driven aggregation, while the two tyrosine
kinase inhibitors will provide information on the mechanism of
aggregation. Src and Syk tyrosine kinases mediate activation of
platelets by a group of single transmembrane receptors which
signal through an immunoreceptor-tyrosine-based-activation-
motif (ITAM) namely GPVI, CLEC-2 and FcgRIIA. These three
receptors are activated by clustering which is the likely mech-
anism of activation by the polyvalent nanoparticles.
Prior to the stimulation of platelets by nanoparticles, the
platelets were incubated separately with the inhibitors for
2 min. The eﬀect of the inhibitor was compared to vehicle-
treated (DMSO) controls. The dose that produced maximal
platelet aggregation for both sizes (log10 2.4 cm
2 ml1) of
nanoparticle was used.
All three inhibitors caused a partial (50–70%) inhibition of
platelet activation to both sizes of Pt nanoparticles (Fig. 5). The
partial inhibition by Integrilin demonstrates that aggregation is
composed of two phases, agglutination (which is not blocked by
Integrilin) and integrin aIIbb3-mediated aggregation (which is
blocked by Integrilin). The similar inhibitory eﬀect of dasatinib
and PRT-060318 demonstrates that activation of integrin aIIbb3This journal is © The Royal Society of Chemistry 2018is likely to be mediated by one or more of the three ITAM
receptors described above. The mechanism of agglutination
could be through neutralisation of platelet surface charge
leading to binding of membrane proteins to each other. Inter-
estingly, a similar prole of results has been reported for acti-
vation of human and mouse platelets by diesel exhaust
particles, with activation mediated by GPVI with a minor
contribution of CLEC-2.25Conclusions
In conclusion, the present study shows that the activation of
platelets by two types of nanoparticles, both of which have an
overall negative charge, is governed by their surface area and
not the size, and that the dose response curve for activation is
bell shaped. Activation of platelets is mediated by passive
agglutination and activation of integrin aIIbb3 through
a pathway regulated by Src and Syk tyrosine kinase (likely
through crosslinking of GPVI and CLEC-2). The relationship
between nanoparticle surface area and platelet activation, irre-
spective of nanoparticle surface type, is consistent with cross-
linking of surface receptors being a key determinant in
inducing platelet activation. The bell-shaped nature of the dose
response curve could reect repelling of platelets from each due
to the charge of the particles. The results have important
implication for the design of nanoparticles in targeting surface
receptors and understanding surface interactions of platelets
with foreign bodies.Conﬂicts of interest
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